High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy.
A new high-performance liquid chromatographic method for the determination of efavirenz in human plasma is described. Quantitative recovery following liquid-liquid extraction with diethylether from 200 microl of human plasma was achieved. Subsequently, the assay was performed with 67 mM potassium dihydrogen phosphate-acetonitrile as a mobile phase, a XTerraRP 18 column protected with a Phenomenex C18 column and UV detection at 246 nm. Linear standard curves were obtained for concentrations ranging from 25 to 15,000 ng/ml. The calculated intra- and inter-day coefficients of variation were below 10%.
Langmann
P
P
University of Würzburg, Department of Internal Medicine, Germany. p.langmann@medizin.uni-wuerzburg.de
Schirmer
D
D
Väth
T
T
Zilly
M
M
Klinker
H
H
D000480:Alkynes; D019380:Anti-HIV Agents / Q000097:blood*; D048588:Benzoxazines; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003521:Cyclopropanes; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D015497:HIV-1; D006801:Humans; D010078:Oxazines / Q000097:blood* / Q000592:standards; D018894:Reverse Transcriptase Inhibitors / Q000097:blood*; D012680:Sensitivity and Specificity
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz